Cancer drugs whose price reduction was announced in the Union budget are used in a minority of cases while many other ...
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback